---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-022006"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:19:43.808320+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing

## Summary
- Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).
- Revenue in 2025 fell to $39.6M from $57.8M; Q4 revenue $14.2M up from $7.6M, driven by Pfizer and Lilly collaborations.
- Cash and equivalents $20.9M as of Dec 31; expects funding into Q3 2026 after recent $25M offering and other receipts.
- Rolling BLA submission to FDA for ST-920 (Fabry gene therapy) in progress; CMC module expected summer 2026 subject to funding.
- Neurology pipeline advancing: Phase 1/2 STAND study for ST-503 in chronic pain with six sites activated; Eli Lilly capsid license added.

## SEC filing metadata
- accession: 0001628280-26-022006
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/0001628280-26-022006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/sgmo-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-022006
- JSON: https://secwatch.observer/filing/0001628280-26-022006.json
- Plain text: https://secwatch.observer/filing/0001628280-26-022006.txt

## Key facts
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported fourth quarter ended December 31, 2025 results: revenue $14.2 million, net income $37.4 million, EPS $0.11 per share.
  - Period: fourth quarter ended December 31, 2025
  - Revenue: $14.2 million
  - Net income: $37.4 million
  - EPS: $0.11 per share
  - Result: reported results
  source text: to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/0001628280-26-022006-index.htm
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported year ended December 31, 2025 results: revenue $39.6 million, net income $122.9 million, EPS $0.44 per share.
  - Period: year ended December 31, 2025
  - Revenue: $39.6 million
  - Net income: $122.9 million
  - EPS: $0.44 per share
  - Result: reported results
  source text: For the year ended December 31, 2025, consolidated net loss was $122.9 million, or $0.44 per share, compared to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s exercise of its option to obtain a license pursuant to the terms of the 2008 licensing agreement for certain zinc finger modified cell lines, an increase of $1.0 million in revenue relating to our collaboration agreement with Astellas, and $0.4 million in revenue from research services relating to our capsid license agreement with Lilly, partially offset by $0.8 million in revenue relating to our collaboration agreement with Genentech recognized in 2024. Revenues were $39.6 million in 2025, compared to $57.8 million in 2024. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/0001628280-26-022006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.